Not Yet Recruiting
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
NCT07475026
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
Not specified